参考文献/References:
[1]Jemal A, Siegel R, Ward E, et al. Cancer statistics.CA Cancer J Clin,2009,59(7):225-249.
[2]Rose SL, Goodheart MJ, DeYoung BR, et al.P21 expression predicts outcome in p53-null ovarian carcinoma. Clin Cancer Res,2003,9(3):1028-1032.
[3]Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Patho1,2004,164(5):1511-1518.
[4]Dubeau L, Drapkin R. Coming into focus: the nonovarian origins of ovarian cancer. Annals of Oncol，2013,24(8):28-35.
[5]刘从容,郑文新.卵巢癌发生机制研究进展.中华病理学杂志,2011, 40（8）：569-572.
[6]Waters L, Crumley S, Truong L, et al.PAX 2 and PAX 8:Useful marker for metastatic effusion. J Clin Cytol and Cytopathol,2014,58(1):105-122.
[7]Lauchlan SC．The secondary Mullerian system．Obstet Gynecol Surv，1972，27(3)：133-146．
[8]Singer G, Kuman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Rm J Pathol，2002,160（4）:1223-1228.
[9]Kuman RJ,Shih Iem.Pathogenesis of ouarian cancer: lessons from morphology and molecular biology and their clinical implications.Int J Gynecol Pathol,2008,27(2):151-161.
[10]Vang R, Shih IeM, Kurman RJ.Ovarian low-grade and high-grade serous carcinoma: pathogenesis， clinicopathologic and molecular biologic features，and diagnostic problems. Adv Anal Pathol,2009,16(5):267-282.
[11]郭东辉，郑文新，申彦,等.对卵巢浆液性癌的新认识.诊断病理学杂志,2011,18（4）:308-310.
[12]Lee Y，Miron A，Drapkin R，et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol，2007,211(1):26-35.
[13]Kuo KT, Guan B, Feng Y. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Gynecol Oncol,2005,97(1):219-222.
[14]Finch A，Shaw P，Rosen B，et a1．Clinical and pathologic findings of prophylactic：salpingo-oophorectomies in159 BRCAl and BRCA2 carriers．Gynecol Oncol，2006，100(2):58-64.
[15]孔北华.卵巢上皮性癌的二元理论和卵巢外起源学说.中华妇产科杂志，2013,48（4）:310-313.
[16]Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serious ovarian cancer and its clinical impact. J Clin Oncol,2008,26(32):5284-5293.
[17]Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol，2011,42(7):918-931.
[18]Stern RC, Dash R. Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol，2001,20（4）:133-139.
[19]Ogawa S，Kaku T，Amada S，et al．Ovarian endometriosis associated with ovarian carcinoma：a clinic pathological and immunohistochemical study．Gynecol Oncol，2000,77(2)：298-304.
[20]Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. New England J Med,2010,363（16）:1532-1537.
[21]Higashiura Y, Kajihara H, Shigetomi H,et al. Identification of multiple pathways involved in the malignant transformation of endometriosis(review）.Oncol Lett,2012,4（1）:3-9.
[22]Somigliana E, Vigano P, Parazzini F, et al. Association between endometriosis and cancer:a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol，2006,101(2):331-341.
[23]van der Horst PH, van der Zee M, Heijmans-Antonissen C,et al. A mouse model for endometrioid ovarian cancer arising from the distal oviduct. Int J Cancer,2014,135(5):1028-1037.
[24]Seidman JD，Khedrnati F．Exploring the histogensis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthafd cell nests：a study of 120 tumors．Arch Pathol Lab Med,2008,32(11):1753-1760．
[25]李杰,王立杰，相丽，等.卵巢癌的二元论模型及细胞起源与发病机制.中华妇产杂志,2011,46（10）:792-795.
[26]Bosincu L，Massarelli G，Cossu Rocea P, et al. Rectal endometrial stromal arising in endometriosis：report of a case. Discolon Rectum,2001,44(6):890-892．
[27]张众，李连宏，王华新，等.癌肉瘤的上皮-间叶转变.临床与实验病理学杂志,2011,27（1）：79-81.